Clinical significance and prognostic role of hypoxia-induced microRNA 382 in gastric adenocarcinoma


Autoři: An Na Seo aff001;  Yukdong Jung aff003;  Hyeonha Jang aff003;  Eunhye Lee aff001;  Han-Ik Bae aff001;  Taekwon Son aff005;  Ohkyung Kwon aff006;  Ho Young Chung aff007;  Wansik Yu aff006;  You Mie Lee aff003
Působiště autorů: Department of Pathology, School of Medicine, Kyungpook National University, Daegu, South Korea aff001;  Department of Pathology, Kyungpook National University Chilgok Hospital, Daegu, South Korea aff002;  BK21 Plus KNU Multi-Omics Based Creative Drug Research Team, College of Pharmacy, Kyungpook National University, Daegu, South Korea aff003;  Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu, South Korea aff004;  Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea aff005;  Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea aff006;  Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea aff007
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223608

Souhrn

Hypoxia and angiogenesis are critical components in the progression of solid cancer, including gastric cancers (GCs). miR-382 has been identified as a hypoxia-induced miR (hypoxamiR), but the clinical significance in GCs has not been identified yet. To explore the clinical and prognostic importance of miR-382 in GCs, the surgical specimens of 398 patients with GCs in KNU hospital in Korea, the total of 183 patients was randomly selected using simple sampling methods and big data with 446 GCs and 45 normal tissues from the data portal (https://portal.gdc.cancer.gov/) were analysed. Expression of miR-382 as well as miR-210, as a positive control hypoxamiR by qRT-PCR in histologically malignant region of GCs showed significantly positive correlation (R = 0.516, p<0.001). High miR-210 and miR-382 expression was significantly correlated with unfavorable prognosis including advanced GCs (AGC), higher T category, N category, pathologic TNM stage, lymphovascular invasion, venous invasion, and perinueral invasion, respectively (all p<0.05). In univariate analysis, high miR-210 expression was significantly associated with worse overall survival (OS) (p = 0.036) but not high miR-382. In paired 60 gastric normal and cancer tissues, miR-382 expression in cancer tissues was significantly higher than normal counterpart (p = 0.003), but not miR-210 expression. However, by increasing the patient number from the big data analysis, miR-210 as well as miR-382 expression in tumor tissues was significantly higher than the normal tissues. Our results suggest that miR-382, as novel hypoxamiR, can be a prognostic marker for advanced GCs and might be correlated with metastatic potential. miR-382 might play important roles in the aggressiveness, progression and prognosis of GCs. In addition, miR-382 give a predictive marker for progression of GCs compared to the normal or preneoplastic lesion.

Klíčová slova:

Adenocarcinomas – Gastric cancer – Gastrointestinal tract – Hypoxia – Medical hypoxia – MicroRNAs – Prognosis – Angiogenesis


Zdroje

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. Epub 2015/02/06. doi: 10.3322/caac.21262 25651787.

2. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141–8. Epub 2014/10/16. doi: 10.1093/annonc/mdu472 25316259.

3. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. Epub 2014/09/23. doi: 10.1016/S1470-2045(14)70420-6 25240821.

4. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004;10(7):2299–306. Epub 2004/04/10. 15073105.

5. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol. 2006;58(6):776–84. doi: 10.1007/s00280-006-0224-7 16532342.

6. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008;7(7):1961–73. Epub 2008/07/23. doi: 10.1158/1535-7163.MCT-08-0198 18645006.

7. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14(3):191–201. Epub 2011/04/07. doi: 10.1016/j.drup.2011.03.001 21466972.

8. Doktorova H, Hrabeta J, Khalil MA, Eckschlager T. Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):166–77. Epub 2015/05/23. doi: 10.5507/bp.2015.025 26001024.

9. Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47–71. Epub 2013/08/14. doi: 10.1146/annurev-pathol-012513-104720 23937437.

10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. Epub 2004/01/28. doi: S0092867404000455 [pii]. doi: 10.1016/s0092-8674(04)00045-5 14744438.

11. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(24):15524–9. Epub 2002/11/16. doi: 10.1073/pnas.242606799 12434020; PubMed Central PMCID: PMC137750.

12. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer research. 2005;65(16):7065–70. Epub 2005/08/17. doi: 10.1158/0008-5472.CAN-05-1783 16103053.

13. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28(3–4):369–78. Epub 2009/12/17. doi: 10.1007/s10555-009-9188-5 20012925.

14. Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2(12):1117–33. Epub 2012/08/07. doi: 10.1177/1947601911423654 22866203; PubMed Central PMCID: PMC3411127.

15. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283(23):15878–83. Epub 2008/04/18. doi: 10.1074/jbc.M800731200 18417479; PubMed Central PMCID: PMC3259646.

16. Seok JK, Lee SH, Kim MJ, Lee YM. MicroRNA-382 induced by HIF-1alpha is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. Nucleic Acids Res. 2014;42(12):8062–72. Epub 2014/06/11. doi: 10.1093/nar/gku515 24914051; PubMed Central PMCID: PMC4081109.

17. Dang K, Myers KA. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci. 2015;16(3):6353–72. Epub 2015/03/27. doi: 10.3390/ijms16036353 25809609; PubMed Central PMCID: PMC4394536.

18. Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell. 2004;5(5):405–6. Epub 2004/05/18. doi: S1535610804001187 [pii]. 15144945.

19. Yoo SB, Lee HJ, Park JO, Choe G, Chung DH, Seo JW, et al. Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study. Lung Cancer. 2010;67(3):301–5. Epub 2009/06/10. doi: 10.1016/j.lungcan.2009.05.002 19505745.

20. Edge SB, Byrd DR, Compton C, Fritz A, Greene F, Trotti A. American joint committee on cancer staging manual. American Joint Committee on Cancer Staging Manual. 2010.

21. Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670–80. Epub 2011/12/20. doi: 10.1002/cncr.26711 22180017.

22. Kirsch R, Messenger DE, Riddell RH, Pollett A, Cook M, Al-Haddad S, et al. Venous invasion in colorectal cancer: impact of an elastin stain on detection and interobserver agreement among gastrointestinal and nongastrointestinal pathologists. Am J Surg Pathol. 2013;37(2):200–10. Epub 2012/10/31. doi: 10.1097/PAS.0b013e31826a92cd 23108018.

23. Soo KC, Carter RL, O'Brien CJ, Barr L, Bliss JM, Shaw HJ. Prognostic implications of perineural spread in squamous carcinomas of the head and neck. The Laryngoscope. 1986;96(10):1145–8. Epub 1986/10/01. doi: 10.1288/00005537-198610000-00015 3762289.

24. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379–91. Epub 2009/06/02. doi: 10.1002/cncr.24396 19484787.

25. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137–46. Epub 2007/05/04. doi: 10.1172/JCI31405 17476343; PubMed Central PMCID: PMC1857231.

26. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A microRNA signature of hypoxia. Molecular and cellular biology. 2007;27(5):1859–67. Epub 2006/12/30. doi: 10.1128/MCB.01395-06 17194750; PubMed Central PMCID: PMC1820461.

27. Huang X, Le QT, Giaccia AJ. MiR-210—micromanager of the hypoxia pathway. Trends Mol Med. 2010;16(5):230–7. Epub 2010/05/04. doi: 10.1016/j.molmed.2010.03.004 20434954; PubMed Central PMCID: PMC3408219.

28. Kiga K, Mimuro H, Suzuki M, Shinozaki-Ushiku A, Kobayashi T, Sanada T, et al. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. Nature communications. 2014;5:4497. Epub 2014/09/05. doi: 10.1038/ncomms5497 25187177; PubMed Central PMCID: PMC4279363.

29. Bar I, Merhi A, Abdel-Sater F, Ben Addi A, Sollennita S, Canon JL, et al. The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2017;65(6):335–46. Epub 2017/04/14. doi: 10.1369/0022155417702849 28402752; PubMed Central PMCID: PMC5625853.

30. Zhou X, Zhu W, Li H, Wen W, Cheng W, Wang F, et al. Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. Scientific reports. 2015;5:11251. Epub 2015/06/11. doi: 10.1038/srep11251 26059512; PubMed Central PMCID: PMC4462022.

31. Qi B, Lu JG, Yao WJ, Chang TM, Qin XG, Ji YH, et al. Downregulation of microRNA-382 is associated with poor outcome of esophageal squamous cell carcinoma. World journal of gastroenterology. 2015;21(22):6884–91. Epub 2015/06/17. doi: 10.3748/wjg.v21.i22.6884 26078564; PubMed Central PMCID: PMC4462728.

32. Xu M, Jin H, Xu CX, Sun B, Mao Z, Bi WZ, et al. miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma. Oncotarget. 2014;5(19):9472–83. Epub 2014/10/27. doi: 10.18632/oncotarget.2418 25344865; PubMed Central PMCID: PMC4253447.

33. Ho JY, Hsu RJ, Liu JM, Chen SC, Liao GS, Gao HW, et al. MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis. Oncotarget. 2017;8(14):22443–59. Epub 2016/10/06. doi: 10.18632/oncotarget.12338 27705918; PubMed Central PMCID: PMC5410235.

34. Rotkrua P, Shimada S, Mogushi K, Akiyama Y, Tanaka H, Yuasa Y. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer. 2013;108(4):932–40. Epub 2013/02/07. doi: 10.1038/bjc.2013.30 23385731; PubMed Central PMCID: PMC3590667.

35. Patnaik SK, Mallick R, Yendamuri S. Detection of microRNAs in dried serum blots. Anal Biochem. 2010;407(1):147–9. Epub 2010/08/11. doi: 10.1016/j.ab.2010.08.004 20696125; PubMed Central PMCID: PMC2947447.

36. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Molecular cell. 2009;35(6):856–67. Epub 2009/09/29. doi: 10.1016/j.molcel.2009.09.006 19782034; PubMed Central PMCID: PMC2782615.


Článek vyšel v časopise

PLOS One


2019 Číslo 10

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se